![Yury Kukushkin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yury Kukushkin
Directeur/Membre du Conseil chez
Veralox Therapeutics, Inc.
Profil
Yury Kukushkin became a Managing Director for the T1D Fund in 2022 after joining as an Investment Director in 2019 from 4BIO Capital, a London-based fund investing in public and private life sciences companies.
While there, he focused on gene and cell therapies, PROTACs, RNA medicines, and targeted therapies and delivered top quartile returns for the fund.
Prior to this role, Yury was Chief Analyst and Associate at RBV Capital, an early-stage life sciences venture fund.
Earlier in his career, Yury worked in various roles in a boutique consulting company Abercade supporting over 20 various investment deals with US-based venture-backed companies.
Originally from Moscow, Russia, Yury received his M.S.
in Biochemistry with specialization in Virology from Moscow State University and a Ph.D.
in Cellular Biochemistry from Max Planck Institute of Biochemistry, Martinsried, Germany.
Postes actifs de Yury Kukushkin
| Sociétés | Poste | Début |
|---|---|---|
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Directeur/Membre du Conseil | 01/12/2020 |
Code Biotherapeutics, Inc.
 Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Directeur/Membre du Conseil | 01/03/2021 |
Hevolution Foundation
 Hevolution Foundation Investment Trusts/Mutual FundsMiscellaneous Operates as a non-profit funding, grants and early-stage investment organization | Corporate Officer/Principal | 01/09/2023 |
Anciens postes connus de Yury Kukushkin
| Sociétés | Poste | Fin |
|---|---|---|
4bio Capital Partners
 4bio Capital Partners Investment ManagersFinance Acts as an alternative investment manager | Private Equity Investor | 01/09/2023 |
JDRF T1D Fund
 JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements. | Private Equity Investor | 01/09/2023 |
Formation de Yury Kukushkin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Moscow State University Lomonosov
 Moscow State University Lomonosov Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Max Planck Institute of Biochemistry
 Max Planck Institute of Biochemistry Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
JDRF T1D Fund
JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements. | Finance |
4bio Capital Partners
4bio Capital Partners Investment ManagersFinance Acts as an alternative investment manager | Finance |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Hevolution Foundation
Hevolution Foundation Investment Trusts/Mutual FundsMiscellaneous Operates as a non-profit funding, grants and early-stage investment organization | Miscellaneous |
